Business Description
Atrium Therapeutics Inc
NAICS : 541714
SIC : 2836
ISIN : US04965N1046
Description
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 99.94 | |||||
Equity-to-Asset | 0.8 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.04 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 2.81 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -13.55 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.04 | |||||
9-Day RSI | 67.17 | |||||
14-Day RSI | 61.8 | |||||
3-1 Month Momentum % | -8.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 13.04 | |||||
Quick Ratio | 13.04 | |||||
Cash Ratio | 12.23 | |||||
Days Sales Outstanding | 267.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | 1.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -318.7 | |||||
Net Margin % | -315.71 | |||||
EBITDA Margin % | -317.37 | |||||
FCF Margin % | -256.14 | |||||
OCF Margin % | -245.9 | |||||
ROE % | -29.67 | |||||
ROA % | -22.88 | |||||
ROIC % | -225.64 | |||||
ROC (Joel Greenblatt) % | -1078.4 | |||||
ROCE % | -26.03 | |||||
Moat Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 11.39 | |||||
PB Ratio | 1 | |||||
Price-to-Tangible-Book | 1 | |||||
EV-to-EBIT | 0.48 | |||||
EV-to-EBITDA | 0.49 | |||||
EV-to-Revenue | -1.55 | |||||
EV-to-FCF | 0.6 | |||||
| Price-to-Net-Current-Asset-Value | 1.03 | |||||
| Price-to-Net-Cash | 1.11 | |||||
Earnings Yield (Greenblatt) % | 208.33 | |||||
FCF Yield % | -22.48 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RNA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Atrium Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20.494 | ||
| EPS (TTM) ($) | -3.78 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 61.8 | ||
| 14-Day ATR ($) | 0.508274 | ||
| 20-Day SMA ($) | 12.649 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 11.4031 - 16.77 | ||
| Shares Outstanding (Mil) | 17.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Atrium Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Atrium Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Atrium Therapeutics Inc Frequently Asked Questions
What is Atrium Therapeutics Inc(RNA)'s stock price today?
The current price of RNA is $13.65. The 52 week high of RNA is $16.77 and 52 week low is $11.40.
When is next earnings date of Atrium Therapeutics Inc(RNA)?
The next earnings date of Atrium Therapeutics Inc(RNA) is .
Does Atrium Therapeutics Inc(RNA) pay dividends? If so, how much?
Atrium Therapeutics Inc(RNA) does not pay dividend.
Guru Commentaries on NAS:RNA
No articles.
Press Release
Articles on Atrium Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers